Summary
Pfizer Inc. (PFE) filed an 8-K on January 12, 2021, to disclose preliminary financial guidance for the fiscal year 2021. The company projects adjusted diluted earnings per share (EPS) to be in the range of $3.00 to $3.10. This guidance is subject to various assumptions and uncertainties, including the ongoing impact of the COVID-19 pandemic, vaccine supply, and related contracts. Further details regarding this guidance and Pfizer's financial outlook are expected to be provided on February 2, 2021, when the company announces its fourth-quarter and full-year 2020 financial results. Investors should note that this preliminary guidance is based on non-GAAP measures, and Pfizer does not provide forward-looking GAAP guidance due to the unpredictability of certain items such as litigation costs and acquisition expenses.
Key Highlights
- 1Pfizer provided preliminary 2021 adjusted diluted EPS guidance of $3.00 - $3.10.
- 2This guidance is subject to significant uncertainties, including the COVID-19 pandemic and vaccine-related factors.
- 3A more comprehensive discussion of financial guidance will occur on February 2, 2021, with Q4 2020 earnings.
- 4The company reiterates its focus on its core business of prescription medicines and vaccines.
- 5Pfizer utilizes non-GAAP measures for guidance, citing the inability to predict certain GAAP-impacting items like litigation and acquisition costs.
- 6The filing includes an extensive list of forward-looking statements and risk factors relevant to the company's operations and future performance, particularly concerning COVID-19 vaccine development and supply.